View Financial HealthRenol Polychem 配当と自社株買い配当金 基準チェック /06Renol Polychem配当金を支払った記録がありません。主要情報n/a配当利回り-160.9%バイバック利回り総株主利回り-160.9%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.お知らせ • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).お知らせ • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.お知らせ • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation SBoard Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.決済の安定と成長配当データの取得安定した配当: RNPLの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RNPLの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Renol Polychem 配当利回り対市場RNPL 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RNPL)n/a市場下位25% (IN)0.3%市場トップ25% (IN)1.5%業界平均 (Chemicals)0.8%アナリスト予想 (RNPL) (最長3年)n/a注目すべき配当: RNPLは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RNPLは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RNPLの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RNPLが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 00:06終値2026/06/11 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Renol Polychem Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹6.83 (vs ₹9.10 in FY 2025)Full year 2026 results: EPS: ₹6.83. Revenue: ₹902.3m (up 44% from FY 2025). Net income: ₹82.5m (up 65% from FY 2025). Profit margin: 9.1% (up from 8.0% in FY 2025). The increase in margin was driven by higher revenue.
お知らせ • May 27Renol Polychem Limited to Report Second Half, 2026 Results on May 29, 2026Renol Polychem Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹109, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 21x in the Chemicals industry in India.
New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹965.6m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (65% accrual ratio). Market cap is less than US$10m (₹965.6m market cap, or US$9.97m).
お知らせ • Nov 13Renol Polychem Limited to Report First Half, 2026 Results on Nov 13, 2025Renol Polychem Limited announced that they will report first half, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹90.00, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 26x in the Chemicals industry in India.
お知らせ • Aug 06Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million.Renol Polychem Limited has completed an IPO in the amount of INR 257.67 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 148,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 384,000 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 256,800 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 349,200 Price\Range: INR 105 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,315,200 Price\Range: INR 105 Transaction Features: Regulation S
Board Change • Aug 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Executive Director Naitik Harsoda is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.